<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141241">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01917383</url>
  </required_header>
  <id_info>
    <org_study_id>IPC-01-2013</org_study_id>
    <nct_id>NCT01917383</nct_id>
  </id_info>
  <brief_title>A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma</brief_title>
  <official_title>A Phase II Multi-center, Randomized Study to Evaluate the Monocular Addition of Trabodenoson (INO-8875) Ophthalmic Formulation to Latanoprost Ophthalmic Solution Therapy in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inotek Pharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inotek Pharmaceuticals Corporation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the intraocular pressure (IOP) lowering efficacy
      and the safety and tolerability profile of trabodenoson ophthalmic formulation compared to
      timolol maleate ophthalmic solution 0.5% in adults with ocular hypertension (OHT) or primary
      open-angle glaucoma (POAG) who are already receiving treatment with latanoprost ophthalmic
      solution 0.005% once every evening (QPM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Criteria

      Inclusion Criteria:

        1. Subject has signed and dated the current informed consent form (ICF).

        2. Subject has the diagnosis of ocular hypertension (OHT) or primary open-angle glaucoma
           (POAG) (excluding secondary, pseudo-exfoliation, and pigment dispersion glaucomas).

        3. Aged 18 or older.

        4. Mean intraocular pressure (IOP) of ≥24 and ≤34 mm Hg.

      Exclusion Criteria:

        1. No significant visual field loss or any new field loss within the past year.

        2. Cup-to-disc ratio ≥0.8

        3. Central corneal thickness &lt;500 µm or &gt;600 µm

        4. A recent (acute) or chronic medical condition that might obfuscate the Subject's study
           data
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Intraocular Pressure (IOP)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Primary Open-Angle Glaucoma (POAG) and Ocular Hypertension (OHT)</condition>
  <arm_group>
    <arm_group_label>Trabodenoson Plus Latanoprost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental ophthalmic eye drop plus a prostaglandin analogue eye drop</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Timolol Plus Latanoprost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A Beta-blocker eye drop plus a prostaglandin analogue eye drop</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trabodenoson</intervention_name>
    <description>Ophthalmic eye drop</description>
    <arm_group_label>Trabodenoson Plus Latanoprost</arm_group_label>
    <arm_group_label>Timolol Plus Latanoprost</arm_group_label>
    <other_name>INO-8875</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has signed and dated the current informed consent form (ICF).

          2. Subject has the diagnosis of ocular hypertension (OHT) or primary open-angle glaucoma
             (POAG) (excluding secondary, pseudo-exfoliation, and pigment dispersion glaucomas).

          3. Aged 18 or older.

          4. Mean intraocular pressure (IOP) of ≥24 and ≤34 mm Hg.

        Exclusion Criteria:

          1. No significant visual field loss or any new field loss within the past year.

          2. Cup-to-disc ratio ≥0.8

          3. Central corneal thickness &lt;500 µm or &gt;600 µm

          4. A recent (acute) or chronic medical condition that might obfuscate the Subject's
             study data
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Janet Combs</last_name>
    <phone>423-968-9533</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Audrey Rossow, BA</last_name>
    <phone>508-808-5489</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chiltern</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Combs, BS</last_name>
      <phone>423-990-0361</phone>
      <email>Janet.Combs@chiltern.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 19, 2013</lastchanged_date>
  <firstreceived_date>August 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>primary open angle glaucoma</keyword>
  <keyword>ocular hypertension</keyword>
  <keyword>adenosine agonist</keyword>
  <keyword>eye drop</keyword>
  <keyword>trabodenoson</keyword>
  <keyword>trabecular meshwork</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
